Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Rose K who wrote (48393)	7/3/1999 9:29:00 PM
From: Jenna	Read Replies (7) \| Respond to of 120523

Biotechs.. I have always had a special penchant for this sector, and paradoxically its the one sector that alludes me because of all the 'scientific and technological' expertise needed to evaluate, not the fundamentals, but the drugs themselves.. Anyhow I've come across an article about New drugs that have an advantage of chemotherapy in trying to eradicate cancer. I've read an intriguing and heart wrenching article in Business Week about Gene Therapy and another article in Money World.. They mention drugs that might just be reaching the marketplace that are extremely promising. Two of the companies I either have had or am contemplating picking up: ImClone Systems (IMCL).. has developed C222, a new antibody injected into patients with inoperable tumors in the head or neck. According to the Wall Streeet Journal, C225, which was recently tested by oncologists, completely or partially eradicated tumors in all 15 test patients when combined with radiation. It is estimated that radiation alone would have had up to a 50% response rate. Pfizer is also working with Hoechtst Marion Rousel, a subsidiary to Hoechst AG (ADR: hoe) to introduce an insulin inhalant, which is expected to have tremendous growth potential. Other companies, such as Sugen Inc. (SUGN) are working on an entirely new class of tumor-fighting drugs. This discrete category of drugs will atempt to halt a tumor's blood-making capabilities. Some drugs stocks look to be about to regain their former lofty levels: Drug companies such as SGP, with its Claritin are filling prime time commercial spots and are seen in top magazines. Breakthroughs in biotechnology are also jump-starting the industry. Advances from major players Centocor (CNTO), Immunex Corp. (IMNX) and IDEC pharmaceuticals among others have fueled higher profits. Kolbert's number pick (of Solomen Smith Barney) in the drug sector is Pfizer because of the compnay's successful products, the diversity of its medciations and its strongly held patents. He added that Pfizer's top three drugs -- Viagra Lipitor and Celebrex - have he ability to bring revenues of $7.5 billion in 2002. Other favorites include BMY, LLY and MDT.. by the way just to make clear, I do hold positions in CNTO, CHRX, MDT,IMNX, and looking to get into IMCL and SUGN... I also have CEGE (a gene therapy drug in the fight against aids and cancer), AZA, SEPR, ADRX and MDT.. small positions and I don't know what the future of these drugs will bring but I think they could be good investments as we are all aging, living longer and demanding these advances (imagine trading stocks at the age of 89)and or fighting offshore oil rig fires at the age of 95.